Research out of the University of Manchester suggests Tadalafil (Cialis)—an erectile dysfunction drug that falls in the same class as Viagra—could slow and possibly reverse the progression of heart failure (HF).
Five milligrams of rivaroxaban per day added to a patient’s standard therapy for heart failure (HF) and coronary artery disease (CAD) could reduce that patient’s risk of future thromboembolic events, researchers reported in JAMA Cardiology April 24.
The same genetic variants that have been uncovered in patients with two other types of cardiomyopathy are also present in an uncommonly high proportion of people with cancer therapy-induced cardiomyopathy (CCM), researchers reported in Circulation.
An April 2 story in the New York Times highlighted a potentially dangerous insurance coverage gap faced by heart transplant patients and recipients of other organs—the immunosuppressive drugs they need to prevent organ rejection sometimes aren’t covered by Medicare if they received the transplants before enrolling in the program.
A team-based protocol for treating cardiogenic shock helped one center boost its 30-day survival rates for those patients by nearly 20 percentage points over a two-year period, researchers reported in the Journal of the American College of Cardiology.
A study of nearly 900,000 patients with heart failure or cardiogenic shock revealed their race, insurance coverage and ZIP code were associated with their odds of receiving a left ventricular assist device (LVAD).
Nearly a quarter of heart failure patients discharged after rehabbing in skilled-nursing facilities (SNFs) are bound to get readmitted to hospitals within 30 days of going home. And those whose stay at the SNF two days or fewer are up to four times more likely to be readmitted than those who stay longer.
Compared to warfarin, all direct oral anticoagulants (DOACs) were associated with fewer cardiovascular events including heart attacks and strokes in a study of Medicare patients with both nonvalvular atrial fibrillation and heart failure. But apixaban appeared to offer the best balance of protecting against these events while minimizing bleeding risk.
A new report from Australia highlighted the feasibility of transplanting hearts from donors who have experienced circulatory death—a practice which, if adopted, could expand heart transplant volume by an estimated 20 percent.